Sustained Efficacy of Bazedoxifene in Preventing Fractures in Postmenopausal Women With Osteoporosis: Results of a 5-year, Randomized, Placebo-controlled Study
S. Silverman, J. Adachi(St. Joseph’s Healthcare Hamilton), José Zanchetta(Universidad del Salvador), Harry K. Genant(University of California, San Francisco), Arkadi Chines(Procter & Gamble (United States)), Annie W. C. Kung(University of Hong Kong), Ginger D. Constantine(Université Constantine 2), F. Rio de la Loza(Instituto Nacional de Perinatología), David L. Kendler(University of British Columbia)
Cited by 1
Related Papers
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN-2 FOR TREATMENT OF OPEN TIBIAL FRACTURES
|Journal of Bone and Joint Surgery|2002|1.3k
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
|New England Journal of Medicine|2014|1.2k
Intermittent Etidronate Therapy to Prevent Corticosteroid-Induced Osteoporosis
|New England Journal of Medicine|1997|694